Diffuse Midline Glioma, H3 K27M-Mutant
generalA diffuse midline glioma characterized by the presence of histone H3 K27M mutation.
12
Centers
30
Active Trials
—
Cancer Funding
Specific Cancer Types(1)
| Name | Centers |
|---|---|
| Recurrent Diffuse Midline Glioma, H3 K27M-Mutant | 5 |
Top Centers for Diffuse Midline Glioma, H3 K27M-Mutant(12)
Ranked by research excellence score (trials · grants · publications). Methodology →
| # | Center | Score |
|---|---|---|
| 1 | University of Illinois Cancer CenterChicago, IL High-Volume Research Center | 71.0 |
| 2 | Boston University Cancer CenterBoston, MA High-Volume Research Center | 71.0 |
| 3 | Cancer Center at IllinoisUrbana, IL High-Volume Research Center | 71.0 |
| 4 | Dana-Farber Cancer InstituteBoston, MA NCI Comprehensive Active Research Program | 57.9 |
| 5 | Duke Cancer InstituteDurham, NC NCI Comprehensive Active Research Program | 57.9 |
| 6 | University of Colorado Cancer CenterAurora, CO NCI Comprehensive Active Research Program | 57.9 |
| 7 | University of Cincinnati Cancer CenterCincinnati, OH Active Research Program | 57.9 |
| 8 | NCI Comprehensive Active Research Program | 48.5 |
| 9 | Fred Hutch Cancer CenterSeattle, WA NCI Comprehensive | 39.2 |
| 10 | Herbert Irving Comprehensive Cancer CenterNew York, NY NCI Comprehensive | 39.2 |
| 11 | Masonic Cancer CenterMinneapolis, MN NCI Comprehensive | 39.2 |
| 12 | Medical College of Wisconsin Cancer CenterMilwaukee, WI | 39.2 |
Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →